Shanghai Henlius Biotech Co. Ltd.
https://www.henlius.com/en/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Henlius Biotech Co. Ltd.
China Biotech Podcast: Going Global Trends, Rare Disease Drug Development
Guest speaker Professor Guangzuo Luo joins Brian Yang and Dexter Yang to discuss orphan drug development and going global trends for Chinese bioventures, along with the latest business moves from Shanghai Fosun and Jiangsu Hengrui.
Fresenius Is Latest To File Denosumab With US FDA
With activity around denosumab biosimilars continuing to heat up, Fresenius Kabi has announced US FDA acceptance of its filing, while China’s Henlius says the EMA is reviewing its own biosimilar submission.
Fosun To Fully Acquire Henlius In Go-Global Push?
Parent Fosun and biosimilars arm Henlius halt share trading on the same day, sparking speculation of a buy-out deal that would assist the Chinese firms' globalization push.
Fosun To Fully Acquire Henlius In Go-Global Push?
Parent Fosun and biosimilars arm Henlius halt share trading on the same day, sparking speculation of a buy-out deal that would assist the Chinese firms' globalization push.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice